(STRO)
Company Description
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company.
It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials.
It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology.
The company was formerly known as Fundamental Applied Biology, Inc.
Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.

Country | United States |
IPO Date | Sep 27, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 310 |
CEO | Jane Chung R.Ph. |
Advertisement
Contact Details
Address: 111 Oyster Point Boulevard South San Francisco, California United States | |
Website | https://www.sutrobio.com |
Stock Details
Ticker Symbol | STRO |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001382101 |
CUSIP Number | 869367102 |
ISIN Number | US8693671021 |
Employer ID | 45-2441988 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jane Chung R.Ph. | Chief Executive Officer & Director |
Edward C. Albini M.B.A | Chief Financial Officer & Secretary |
David Pauling J.D., M.A. | Chief Administrative Officer & General Counsel |
Dr. Anne Elizabeth Borgman-Hagey M.D. | Chief Medical Officer |
Dr. Barbara Leyman Ph.D. | Chief Business Officer |
Dr. Hans-Peter Gerber Ph.D. | Chief Scientific Officer |
Dr. James R. Swartz DSc, Ph.D., Sc.D. | Founder |
Dr. Venkatesh Srinivasan Ph.d. | Chief Technical Operations Officer |
Linda A. Fitzpatrick | Chief People & Communications Officer |
Regina Cheng | Vice President & Controller |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 17, 2025 | SCHEDULE 13G/A | [Amend] Filing |
Apr 15, 2025 | 4 | Filing |
Apr 14, 2025 | PRE 14A | Filing |
Apr 14, 2025 | 8-K | Current Report |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 4 | Filing |
Apr 08, 2025 | 3 | Filing |